Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-off Rhegmatogenous Retinal Detachment

Next Previous
Trial Profile

A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-off Rhegmatogenous Retinal Detachment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ONL 1204 (Primary) ; ONL 1204 (Primary)
  • Indications Dry age-related macular degeneration; Open-angle glaucoma; Retinal detachment
  • Focus Therapeutic Use
  • Sponsors ONL Therapeutics

Most Recent Events

  • 27 Feb 2024 Status changed from active, no longer recruiting to completed.
  • 23 Jan 2024 According to an ONL Therapeutics media release, the company will focus on gathering and analyzing the data with a goal to share topline results in the second quarter of 2024.
  • 23 Jan 2024 According to an ONL Therapeutics media release, data from this study will be presented by David Zacks, M.D., Ph.D, Edna H. Perkiss at the upcoming 47th Annual Meeting of the Macula Society, being held February 7 - 10, 2024, at the La Quinta Resort & Club in Palm Springs, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top